ETON PHARMACEUTIC

Eton Pharmaceuticals avoids costly active ingredient research by optimizing and exclusively marketing proven drugs for rare pediatric and metabolic conditions. New products are sold through the existing sales network to the same specialist physicians, allowing revenues to grow faster than operating costs. The company has reached profitability and plans to achieve long-term EBITDA margins above current levels through organic product expansion and targeted acquisitions. » Więcej na finanzen.net

Eton Pharmaceuticals’ stock rose to a record high of $64.29, bringing its market capitalization to about $1.81 billion. Over the past year the share price gained 271.39%, and revenue increased 81% over the last twelve months. In Q2 2026 adjusted EPS of $0.43 (consensus $0.15) and revenue of $37.6 million (expectation $26.88 million) beat estimates; InvestingPro nonetheless rates the stock as overvalued. » Więcej na de.investing.com

Eton Pharmaceuticals shares climbed to a record high of $55.07 and are currently trading at $54.43, well above the 52-week high of $50.18. In Q2 2026 the company reported adjusted earnings per share of $0.43 (expectation $0.15) and a record revenue of $37.6 million, driven by margin expansion and stronger sales in the rare diseases segment. Market capitalization is about $1.12 billion, trailing-12-month revenue growth is nearly 80%, while InvestingPro rates the stock as overvalued relative to its fair value. » Więcej na de.investing.com

Eton Pharmaceuticals reported Q2 2026 revenue of $37.6 million, well above analyst estimates of $26.88 million, and adjusted EPS of $0.43 versus $0.15 expected. Management raised its 2026 revenue forecast to more than $145 million and showed strong margin improvement: adjusted EBITDA rose to $16.2 million and the EBITDA margin to 43%. H.C. Wainwright reaffirmed its buy rating and raised the price target to $65. The company pointed to pipeline catalysts such as FDA Fast Track designation for AMGLIDIA and the acquisition of hemangioma candidate ASN-001; the stock jumped in after-hours trading toward its 52-week high. » Więcej na de.investing.com

Eton Pharmaceuticals licensed US rights to ASN-001, a topical timolol gel for the treatment of proliferating superficial infantile hemangiomas. In a Phase II/III study with 168 patients, ASN-001 produced clearance or near‑complete clearance at 24 weeks in 56% (twice daily) and 42% (three times daily) of users versus 15% with placebo. Eton plans a bioavailability bridging study and aims to submit a New Drug Application in the second half of 2027; if approved the product would be the first FDA‑approved topical therapy and is patented through 2044. » Więcej na de.investing.com